מדינה: אירלנד
שפה: אנגלית
מקור: HPRA (Health Products Regulatory Authority)
CEFTIOFUR (HYDROCHLORIDE)
Alfasan Nederland B.V
QJ01DD90
CEFTIOFUR (HYDROCHLORIDE)
50 Mg/Ml
Suspension for Injection
POM
Bovine, Porcine
Ceftiofur
Antibacterial
Authorised
2012-03-02
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Alfacef RTU, 50 mg/ml, suspension for injection for cattle and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Ceftiofur 50.0 mg (as Ceftiofur hydrochloride) Excipients: For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Suspension for injection. White to off white coloured suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs (''weighing up to 125 kg''). Cattle. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Infections associated with bacteria sensitive to ceftiofur: In pigs: -Treatment of bacterial respiratory disease associated with_ Pasteurella multocida_,_ Actinobacillus pleuropneumoniae_ and_ Streptococcus suis_. This product is not to be used in pigs with a bodyweight more than 125 kg. In cattle: -Treatment of bacterial respiratory disease associated with_ Mannheimia haemolytica_,_ Pasteurella multocida_ and _Histophilus somni (_previously_ Haemophilus somnus)_. -Treatment of acute interdigital necrobacillosis (panaritium, foul in the foot), associated with_ Fusobacterium_ _necrophorum_ and_ Bacteroides melaninogenicus_ (_Porphyromonas asaccharolytica_). -Treatment of the bacterial component of acute post-partum (puerperal) metritis within 10 days after calving associated with_ Escherichia coli_,_ Arcanobacterium pyogenes_ and_ Fusobacterium necrophorum_, sensitive to ceftiofur_._ The indication is restricted to cases where treatment with another antimicrobial has failed. 4.3 CONTRAINDICATIONS Do not inject intravenously. Do not administer to an animal previously found to be hypersensitive to ceftiofur and other -lactam antibiotics or to any of the excipients. Do not use in poultry (including eggs) due to risk of spread of antimicrobial resistance to humans. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ קרא את המסמך השלם